Differences in response to fetal hemoglobin induction therapy in β-thalassemia and sickle cell disease

Blood Cells, Molecules, and Diseases

Volumn 43, Issue 1, 2009, Pages 58-62

  Fathallah, Hassana ^a   Taher, Ali ^b   Bazarbachi, Ali ^b   Atweh, George F ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Butyrate; Hemin; Hemoglobin expression; Sickle cells; Thalassemia

Indexed keywords

ALPHA GLOBIN; BETA GLOBIN; BUTYRIC ACID; GAMMA GLOBIN; HEMIN; HEMOGLOBIN F;

ADULT; ARTICLE; BETA THALASSEMIA; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; ERYTHROID CELL; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MALE; PHARMACOGENETICS; PRIORITY JOURNAL; SICKLE CELL ANEMIA;

ADULT; ANEMIA, SICKLE CELL; BETA-THALASSEMIA; BUTYRATES; CELLS, CULTURED; ERYTHROID CELLS; FEMALE; FETAL HEMOGLOBIN; GENE EXPRESSION; HEMIN; HEMOGLOBIN SUBUNITS; HEMOGLOBINS; HUMANS; MALE; MIDDLE AGED; RNA, MESSENGER; YOUNG ADULT;

EID: 68649098489     PISSN: 10799796     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcmd.2009.02.006     Document Type: Article

References (23)

1. Bunn H.F. Pathogenesis and treatment of sickle cell disease. N. Engl. J. Med. 337 (1997) 762-769
2. Weatherall D.J. Pathophysiology of thalassaemia. Bailliere's Clin. Haematol. 11 (1998) 127-146
3. Bailey K., Morris J.S., Thomas P., and Serjeant G.R. Fetal haemoglobin and early manifestations of homozygous sickle cell disease. Arch. Dis. Child. 67 (1992) 517-520
4. Stevens M.C., Hayes R.J., Vaidya S., and Serjeant G.R. Fetal hemoglobin and clinical severity of homozygous sickle cell disease in early childhood. J. Pediatr. 98 (1981) 37-41
5. Bollekens J.A., and Forget B.G. Delta beta thalassemia and hereditary persistence of fetal hemoglobin. Hematol./Oncol. Clin. North Am. 5 (1991) 399-422
6. Serjeant G.R. Natural history and determinants of clinical severity of sickle cell disease. Curr. Opin. Hematol. 2 (1995) 103-108
7. Fathallah H., Sutton M., and Atweh G.F. Pharmacological induction of fetal hemoglobin: why haven't we been more successful in thalassemia?. Ann. N.Y. Acad. Sci. 1054 (2005) 228-237
8. Frenette P.S., and Atweh G.F. Sickle cell disease: old discoveries, new concepts, and future promise. J. Clin. Invest. 117 (2007) 850-858
9. Hajjar F.M., and Pearson H.A. Pharmacologic treatment of thalassemia intermedia with hydroxyurea. J. Pediatr. 125 (1994) 490-492
10. Ikuta T., Atweh G., Boosalis V., White G.L., Da Fonseca S., Boosalis M., Faller D.V., and Perrine S.P. Cellular and molecular effects of a pulse butyrate regimen and new inducers of globin gene expression and hematopoiesis. Ann. N.Y. Acad. Sci. 850 (1998) 87-99
11. Ley T.J., DeSimone J., Anagnou N.P., Keller G.H., Humphries R.K., Turner P.H., Young N.S., Keller P., and Nienhuis A.W. 5-azacytidine selectively increases gamma-globin synthesis in a patient with beta+ thalassemia. N. Engl. J. Med. 307 (1982) 1469-1475
12. Ley T.J., DeSimone J., Noguchi C.T., Turner P.H., Schechter A.N., Heller P., and Nienhuis A.W. 5-Azacytidine increases gamma-globin synthesis and reduces the proportion of dense cells in patients with sickle cell anemia. Blood 62 (1983) 370-380
13. Nienhuis A.W., Ley T.J., Humphries R.K., Young N.S., and Dover G. Pharmacological manipulation of fetal hemoglobin synthesis in patients with severe beta-thalassemia. Ann. N.Y. Acad. Sci. 445 (1985) 198-211
14. Loukopoulos D., Voskaridou E., Stamoulakatou A., Papassotiriou Y., Kalotychou V., Loutradi A., Cozma G., Tsiarta H., and Pavlides N. Hydroxyurea therapy in thalassemia. Ann. N.Y. Acad. Sci. 850 (1998) 120-128
15. Charache S., Dover G.J., Moyer M.A., and Moore J.W. Hydroxyurea-induced augmentation of fetal hemoglobin production in patients with sickle cell anemia. Blood 69 (1987) 109-116
16. Fibach E., Prasanna P., Rodgers G.P., and Samid D. Enhanced fetal hemoglobin production by phenylacetate and 4-phenylbutyrate in erythroid precursors derived from normal donors and patients with sickle cell anemia and beta-thalassemia. Blood 82 (1993) 2203-2209
17. Humphries R.K., Dover G., Young N.S., Moore J.G., Charache S., Ley T., and Nienhuis A.W. 5-Azacytidine acts directly on both erythroid precursors and progenitors to increase production of fetal hemoglobin. J. Clin. Invest. 75 (1985) 547-557
18. Fathallah H., Weinberg R.S., Galperin Y., Sutton M., and Atweh G.F. Role of epigenetic modifications in normal globin gene regulation and butyrate-mediated induction of fetal hemoglobin. Blood 110 (2007) 3391-3397
19. Fathallah H., Portnoy G., and Atweh G.F. Epigenetic analysis of the human alpha- and beta-globin gene clusters. Blood Cells Mol. Dis. 40 (2008) 166-173
20. Atweh G.F., and Loukopoulos D. Pharmacological induction of fetal hemoglobin in sickle cell disease and beta-thalassemia. Semin. Hematol. 38 (2001) 367-373
21. Zeng Y.T., Huang S.Z., Ren Z.R., Lu Z.H., Zeng F.Y., Schechter A.N., and Rodgers G.P. Hydroxyurea therapy in beta-thalassaemia intermedia: improvement in haematological parameters due to enhanced beta-globin synthesis. Br. J. Haematol. 90 (1995) 557-563
22. Weinberg R.S., Ji X., Sutton M., Perrine S., Galperin Y., Li Q., Liebhaber S.A., Stamatoyannopoulos G., and Atweh G.F. Butyrate increases the efficiency of translation of gamma-globin mRNA. Blood 105 (2005) 1807-1809
23. Smith R.D., Li J., Noguchi C.T., and Schechter A.N. Quantitative PCR analysis of HbF inducers in primary human adult erythroid cells. Blood 95 (2000) 863-869